In Taiwan, pertussis is a notifiable disease with a low incidence in recent years, and antimicrobial susceptibility testing for the causative agent, Bordetella pertussis, has not been reported to date. In May 2007, the Centers for Disease Control, Taiwan, was informed of a 1-month-old pertussis patient who did not respond to erythromycin treatment. In this study, we report the result of antimicrobial susceptibility testing performed for the suspected erythromycin-resistant isolate, as well as for an additional 27 B. pertussis clinical isolates that represented almost all epidemiologically unrelated isolates obtained throughout Taiwan between 2003 and 2007. All isolates were fully susceptible to azithromycin, erythromycin, clarithromycin and trimethoprim/sulfamethoxazole (MIC ≤0.047 μg ml−1). This result demonstrates the general susceptibility of B. pertussis to antimicrobial agents in vitro in Taiwan.
BartkusJ. M.,
JuniB. A.,
EhresmannK.,
MillerC. A.,
SandenG. N.,
CassidayP. K.,
SaubolleM.,
LeeB.,
LongJ.other authors2003; Identification of a mutation associated with erythromycin resistance in Bordetella pertussis : implications for surveillance of antimicrobial resistance. J Clin Microbiol 41:1167–1172[CrossRef]
BroderK. R.,
CorteseM. M.,
IskanderJ. K.,
KretsingerK.,
SladeB. A.,
BrownK. H.,
MijalskiC. M.,
TiwariT.,
WestonE. J.other authors2006; Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55:1–34
CelentanoL. P.,
MassariM.,
ParamattiD.,
SalmasoS.,
TozziA. E.on behalf of the EUVAC-NET group2005; Resurgence of pertussis in Europe. Pediatr Infect Dis J 24:761–765[CrossRef]
CLSI2006Performance Standards for Antimicrobial Disk Susceptibility Test , 9th edn. approved standard M2–A9 Wayne, PA: Clinical and Laboratory Standards Institute;
GalanakisE.,
EnglundJ. A.,
AbeP.,
QinX.2007; Antimicrobial susceptibility of Bordetella pertussis isolates in the state of Washington. Int J Antimicrob Agents 29:609–611[CrossRef]
GordonK. A.,
FuscoJ.,
BiedenbachD. J.,
PfallerM. A.,
JonesR. N.2001; Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 45:3599–3600[CrossRef]
HillB. C.,
BakerC. N.,
TenoverF. C.2000; A simplified method for testing Bordetella pertussis for resistance to erythromycin and other antimicrobial agents. J Clin Microbiol 38:1151–1155
KorgenskiE. K.,
DalyJ. A.1997; Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States. J Clin Microbiol 35:2989–2991
LangleyJ. M.,
HalperinS. A.,
BoucherF. D.,
SmithB. the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC; 2004; Azithryomycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 114:e96–e101[CrossRef]
LinY. C.,
YaoS. M.,
YanJ. J.,
ChenY. Y.,
ChiangC. S.,
WuH. S.,
LiS. Y.2007; Epidemiological shift in the prevalence of pertussis in Taiwan: implications for pertussis vaccination. J Med Microbiol 56:533–537[CrossRef]
WilsonK. E.,
CassidayP. K.,
PopovicT.,
SandenG. N.2002; Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance. J Clin Microbiol 40:2942–2944[CrossRef]